Brokerages Set Telix Pharmaceuticals Limited (NASDAQ:TLX) Price Target at $21.13

Telix Pharmaceuticals Limited (NASDAQ:TLX) has been assigned an average rating of “Moderate Buy” from the nine research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $21.1250.

Several research firms recently commented on TLX. Wall Street Zen upgraded shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, April 11th. Wedbush reiterated an “outperform” rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Monday, April 13th. Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Monday, April 20th. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Monday, April 13th. Finally, Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, January 19th.

Telix Pharmaceuticals Stock Performance

NASDAQ TLX opened at $11.04 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The company has a 50 day moving average price of $9.01 and a 200 day moving average price of $8.77. Telix Pharmaceuticals has a 52 week low of $6.28 and a 52 week high of $18.49.

Telix Pharmaceuticals (NASDAQ:TLX) last posted its quarterly earnings data on Friday, February 20th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.06). The company had revenue of $206.72 million for the quarter, compared to analysts’ expectations of $421.50 million. Equities research analysts predict that Telix Pharmaceuticals will post 0.09 earnings per share for the current fiscal year.

Institutional Trading of Telix Pharmaceuticals

Several large investors have recently bought and sold shares of TLX. Russell Investments Group Ltd. purchased a new stake in Telix Pharmaceuticals during the 2nd quarter worth approximately $975,000. Jane Street Group LLC purchased a new stake in Telix Pharmaceuticals during the 2nd quarter worth approximately $564,000. IHT Wealth Management LLC purchased a new stake in Telix Pharmaceuticals during the 2nd quarter worth approximately $213,000. Rhumbline Advisers grew its position in Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares during the last quarter. Finally, JPMorgan Chase & Co. purchased a new stake in Telix Pharmaceuticals during the 3rd quarter worth approximately $243,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.